Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 11/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 9/20 | 0.51 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | PAK4 | O96013 | 2/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.38 |
| ▸ | PLK4 | O00444 | 1/20 | 0.37 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4531074 | 0.83 | AURKA (0.47) | AURKAAURKBGSK3BJAK2PAK4 | |
| SCHEMBL4517701 | 0.83 | AURKA (0.47) | AURKAAURKBGSK3BJAK2PAK4 | |
| SCHEMBL4517697 | 0.83 | AURKA (0.47) | AURKAAURKBGSK3BJAK2PAK4 | |
| SCHEMBL4524778 | 0.72 | JAK2 (0.34) | AURKAAURKBJAK2IGF1R | |
| SCHEMBL30250114 | 0.69 | PAK1 (0.51) | AURKAAURKBPAK4PAK1PLK4 | |
| SCHEMBL14605937 | 0.68 | PAK1 (0.69) | AURKBGSK3BJAK2PAK4PAK1 | |
| SCHEMBL4524830 | 0.68 | AURKA (0.41) | AURKAAURKBJAK2PAK4PAK1 | |
| SCHEMBL4524824 | 0.68 | AURKA (0.41) | AURKAAURKBJAK2PAK4PAK1 | |
| SCHEMBL4534020 | 0.68 | AURKA (0.41) | AURKAAURKBJAK2PAK4PAK1 | |
| SCHEMBL14605910 | 0.67 | AURKB (0.39) | AURKAAURKBPAK4PAK1PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281073-A1 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | BHATTACHARYA SAMIT KUMAR | 2009-11-12 | — | — | US | claimed |
| EP-1831216-A2 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2007-09-12 | — | — | EP | claimed |
| WO-2006067614-A2 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2006-06-29 | — | — | WO | claimed |
| US-20090281073-A1 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | BHATTACHARYA SAMIT KUMAR | 2009-11-12 | — | — | US | disclosed |
| EP-1831216-A2 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006067614-A2 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281073-A1 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNY, TP53, CCNE1 | AURKA 401/4885AURKB 519/4885GSK3B 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.